Mesoblast (MESO) vs Vor Biopharma (VOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Vor Biopharma (VOR) has outperformed Mesoblast (MESO) over the past year, gaining 157.6% versus a loss of 29.1%. Over five years, MESO leads with a -12.0% price change compared with -92.0% for VOR. Mesoblast is the larger company by market cap ($1.41 billion vs $1.18 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MESO | VOR |
|---|---|---|
| Share price | $10.89 | $19.19 |
| Market cap | $1.41B | $1.18B |
| 1-day change | -2.59% | +3.62% |
| YTD return | -39.63% | +46.71% |
| 1-year return | -29.15% | +157.58% |
| 5-year return | -12.04% | -92.00% |
| P/E ratio (TTM) | — | 0.06 |
| Forward P/E | 31.11 | — |
| EPS (TTM) | $-0.44 | $300.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $17.20M | — |
| Revenue growth (YoY) | +191.39% | — |
| Net income (latest FY) | $-102.14M | $-695.98M |
| Gross margin | 70.17% | — |
| Net margin | -593.92% | — |
| 52-week high | $21.50 | $26.00 |
| 52-week low | $10.87 | $7.21 |
| Distance from 52-week high | -49.35% | -26.19% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +239.76% | +103.23% |
| Average volume | 240.68K | 945.67K |
| Shares outstanding | 129.85M | 61.43M |
| Employees | 108 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VOR has outperformed MESO by 186.7 percentage points over the past year.
About Mesoblast
MESO stock →Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 108 employees
About Vor Biopharma
VOR stock →Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 76 employees
MESO vs VOR FAQ
Which is bigger, Mesoblast or Vor Biopharma?
Mesoblast (MESO) is larger, with a market capitalization of $1.41B compared with $1.18B for Vor Biopharma (VOR).
Which stock has performed better over the past year, MESO or VOR?
VOR returned +157.58% over the past 12 months, compared with -29.15% for MESO (price return, excluding dividends). Past performance does not predict future results.
Are Mesoblast and Vor Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.